After FDA hold and trial failure, Ipsen writes down its big acquisition — but they're not giving up
Nearly a year ago, at the same time Roche shelled out $4.3 billion on Spark Therapeutics, Paris-based Ipsen bought its own billion-dollar acquisition: Clementia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
